Company Registration No. 3567687 (England and Wales)
Inpharmation Limited
Unaudited accounts
for the year ended 31 March 2023
Inpharmation Limited
Unaudited accounts
Contents
Inpharmation Limited
Company Information
for the year ended 31 March 2023
Directors
Gary Johnson
Karen Johnson
Samuel Johnson
Carla Peek
Kim Robinson
Nicholas Taylor
Robert Watson
Company Number
3567687 (England and Wales)
Registered Office
Evidence House
Stokenchurch Business Park Ibstone Road
Stokenchurch
HP14 3FE
United Kingdom
Accountants
Blue Cube Accountants Limited
Britwell Grange
Britwell Road
Burnham
SL1 8DF
Inpharmation Limited
Statement of financial position
as at 31 March 2023
Intangible assets
12,188
12,188
Tangible assets
2,041,595
2,092,906
Cash at bank and in hand
4,399,955
2,989,285
Creditors: amounts falling due within one year
(936,123)
(788,430)
Net current assets
4,176,020
2,878,429
Total assets less current liabilities
6,229,803
4,983,523
Provisions for liabilities
Deferred tax
(20,286)
(16,389)
Net assets
6,209,517
4,967,134
Called up share capital
105
100
Profit and loss account
6,209,412
4,967,034
Shareholders' funds
6,209,517
4,967,134
For the year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 22 November 2023 and were signed on its behalf by
Carla Peek
Director
Company Registration No. 3567687
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2023
Inpharmation Limited is a private company, limited by shares, registered in England and Wales, registration number 3567687. The registered office is Evidence House, Stokenchurch Business Park Ibstone Road, Stokenchurch, HP14 3FE, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
The patents and licences are not currently being amortised.
Tangible fixed assets and depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land & buildings
2% Straight Line
Plant & machinery
20% Reducing Balance
Motor vehicles
20% Reducing Balance
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2023
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Expenditure on research and development is written off in the year in which it is incurred.
4
Intangible fixed assets
Other
5
Tangible fixed assets
Land & buildings
Plant & machinery
Motor vehicles
Total
Cost or valuation
At cost
At cost
At cost
At 1 April 2022
2,146,027
265,765
53,315
2,465,107
Additions
-
15,624
-
15,624
At 31 March 2023
2,146,027
281,389
53,315
2,480,731
At 1 April 2022
157,566
203,614
11,021
372,201
Charge for the year
42,921
15,555
8,459
66,935
At 31 March 2023
200,487
219,169
19,480
439,136
At 31 March 2023
1,945,540
62,220
33,835
2,041,595
At 31 March 2022
1,988,461
62,151
42,294
2,092,906
Inpharmation Limited
Notes to the Accounts
for the year ended 31 March 2023
Amounts falling due within one year
Trade debtors
694,937
665,944
Accrued income and prepayments
17,246
11,630
7
Creditors: amounts falling due within one year
2023
2022
Trade creditors
21,374
15,271
Taxes and social security
436,053
329,250
Other creditors
29,933
26,045
Loans from directors
1,516
9,202
Allotted, called up and fully paid:
105 Ordinary shares of £1 each
105
100
Shares issued during the period:
5 Ordinary shares of £1 each
5
9
Average number of employees
During the year the average number of employees was 37 (2022: 35).